Articles MINT: opportunities in 'frontier' markets? The prospects for pharma in the MINT emerging countries of Mexico, Indonesia, Nigeria and Turkey.
Views & Analysis New frontiers in pharma: is ‘MINT’ the next ‘BRIC’? MINT countries: what the opportunities may be for pharma and healthcare.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.